In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|May 14, 2026
ACT Brief: Makary's Turbulent FDA Tenure, Pediatric Trial Experience Design, and Weight Loss Maintenance Data
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived experience shapes pediatric trial design and performance, and Eli Lilly's weight loss maintenance data for obesity therapies.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- Marty Makary's 13-month
tenure as FDA Commissioner ended amid leadership instability, internal conflict, and sponsor concerns about regulatory consistency. Six different leaders served as CDER director in a single year, and while Makary introduced accelerated-review initiatives and published 200 complete response letters for transparency, CRL patterns caught sponsors off guard, raising questions about the durability of prior FDA communications and development strategies. - In a new contributed
article , pediatric trial design often overlooks lived experience despite evidence that psychological safety, autonomy, and communication quality influence recruitment, retention, and data integrity. Early palliative care, consent revisited as prognosis evolves, and attention to caregiver burden are increasingly aligned with FDA patient-focused guidance and ICH E6(R3) quality-by-design principles, positioning experience as a structural variable affecting trial performance. - Eli Lilly
reported maintenance-phase data showing patients transitioning from higher-dose injectables to lower-dose Zepbound or oral Foundayo maintained near-complete weight loss through 112 weeks. The findings address weight regain following therapy interruption and reinforce industry recognition that obesity management increasingly resembles chronic disease treatment models requiring ongoing therapy for sustained benefit.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5